“Our company remains focused as tightly as ever on neuro-oncology drug development. We are off to a very rapid start on our lead program, TPI 287, for the treatment of GBM. With the encouraging published body of data established and anticipation of productive discussions with FDA, we remain confident in our ability to drive this program towards the start of our Phase 2 study around year end 2025. Importantly, we have further solidified our financial security with a cash runway into the second half of 2026 which we believe will fund the Company and our operational execution through much of the next planned study of TPI 287,” commented John Climaco, CEO of CNS Pharmaceuticals (CNSP).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- CNS Pharmaceuticals Raises $5M in Public Offering
- CNS Pharmaceuticals acquires Orphan Drug Designation for TPI 287
- CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants
- CNS Pharmaceuticals Advances TPI 287 for Glioblastoma
- CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year